Xenon Looks to Raise Cash for MDD Program with $300M Public Offering

Despite a mid-stage miss, Xenon Pharmaceuticals is forging ahead with its major depressive disorder program and needs cash to do so. Thursday the Canadian company announced a public offering of its shares for total proceeds of $300 million